

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by
Alberta Government sponsored drug programs.

PATIENT INFORMATION				COVERAGE TYPE:
PATIENT LAST NAME	FIRST NAME	INITIAL	<input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other	
DATE OF BIRTH: Year / Month / Day	ALBERTA PERSONAL HEALTH NUMBER			
STREET ADDRESS	CITY	PROV	POSTAL CODE	IDENTIFICATION/CLIENT/COVERAGE No:

PRESCRIBER INFORMATION				
PRESCRIBER LAST NAME	FIRST NAME	INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION	
STREET ADDRESS			<input type="checkbox"/> CPSA <input type="checkbox"/> ACO REGISTRATION NO.	
			<input type="checkbox"/> CARNA <input type="checkbox"/> ADA+C <input type="checkbox"/> ACP <input type="checkbox"/> Other	
CITY , PROVINCE			PHONE:	FAX:
POSTAL CODE			FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED	

Criteria for Coverage of IMIQUIMOD

For the treatment of Actinic Keratosis located on the head and neck in patients who have failed treatment with cryotherapy (where appropriate) and 5-fluorouracil (5-FU). Special authorization may be granted for 6 months. This product is eligible for auto-renewal.

NEW Please provide the following information for NEW requests (check ALL that apply):

Diagnosis:

Actinic Keratosis → Area affected:

Head or neck Other (specify): _____

Other (specify): _____

Previous medications/therapies utilized:

Please indicate if the following medication/therapy have been tried and the response:

1) cryotherapy: Yes → Response:

Lack of response Intolerance Other (specify): _____

No → Not appropriate Other (specify): _____

AND

2) 5-fluorouracil (5-FU): Yes → Response:

Lack of response Intolerance Other (specify): _____

No (specify reason, if applicable): _____

Additional information relating to request

RENEWAL

This product is eligible for auto-renewal. A Special Authorization renewal request is required only if the Special Authorization approval has lapsed (i.e. the patient has not made a claim for the drug product during the Approval Period).

Please indicate response to therapy:

PRESCRIBER'S SIGNATURE	DATE	Please forward this request to: <ul style="list-style-type: none"> ▪ Alberta Blue Cross, Clinical Drug Services ▪ 10009-108 Street NW, Edmonton, Alberta T5J 3C5 ▪ FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas
------------------------	------	---

ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.